ESHO 2026 | Session 4 | OP-038
Therapeutic Integration of Hyperthermia: Bridging the Gap Between Level 1A Evidence and Clinical Reality
Establishing the First National Practice Standards and Regulatory Roadmap in Romania (The SRHO Whitepaper)
M.Sc. Cristian Gologan
Founder & Director, SRHO
With the collaborative support of Prof. Dr. Giammaria Fiorentini & Dr. Hüseyin Şahinbaş
A Core Paradox in Modern Oncology
The unacceptable gap between theoretical guidelines and the oncologist’s practical workbench.
The Scientific Triumph
Hyperthermia is supported by decades of Level 1A evidence. It is formally mandated and recognized in major international clinical practice guidelines, such as ESMO and NCCN.
The Regulatory Void
Despite undeniable efficacy, the lack of a state-regulated institutional framework forces the practice into an administrative “gray zone.” This exposes both patients and self-taught physicians to severe legislative risks.
Level 1A Evidence: The “Multiplier Effect”
Validating massive leaps in Overall Survival (OS), moving beyond marginal clinical gains.
High-Risk Soft Tissue Sarcoma (STS)
✅ ESMO & NCCN GuidelinesMedian OS almost tripled from 6.2 years (Standard) to 15.4 years (Standard + L-R HT), generating an absolute gain of 9.2 years (Issels et al., EORTC 62961).
Locally Advanced Cervical Cancer (LACC)
✅ NCCN (non-chemo) / ⚠️ ESMO GapA 2.5x survival multiplier, with 5-year OS surging to 55.0% compared to ~20% historical baseline, alongside a 33% reduction in death risk (Peters et al. / Lutgens / Datta et al.).
Recurrent Breast Cancer
✅ NCCN (2007) / ✅ ESO-ESMO (2014) ✅ German (DEGRO) ✅ Dutch (Dutch Society for Radiation Oncology)Complete Response (CR) boosted massively to 59-66%, ensuring 68.2% local control at 5 years (Datta et al. / Jones et al.).
Head & Neck Cancers
✅ NCCN / ⚠️ ESMO GapSensitization yields a Mean CR of 61.1% (vs IMRT 39.9%), preserving critical functions like swallowing (Datta et al.).
Esophageal Carcinoma
⚠️ Guideline Gap3-year survival nearly doubled (44.2% vs 24.1%), providing crucial immediate dysphagia relief (Hu et al. / Kitamura / Sugimachi).
Level 1B Evidence: Extensive Cohorts & Efficacy
Driving organ preservation, targeted tumor downstaging, and rapid palliative comfort.
Locally Advanced Rectal Cancer (LARC)
⚠️ Guideline Gap5-year OS leaps to 95.8% (vs 74.5%). Facilitates sphincter-sparing surgeries, avoiding permanent colostomies (Ott et al.).
High-Risk NMIBC (Bladder)
✅ EAU Guidelines / ⚠️ ESMO GapHIVEC protocol increases 10-year Disease-Free Survival by 3.5x (53% vs 15%), saving patients from radical cystectomy (Colombo).
Bone Metastases Palliation
⚠️ Guidline GapProbability of pain elimination increases by up to 9-fold (CR 47.4% vs 5.3% for WBH). Relief in 10 days (Chi / Sahinbas).
Advanced Gastric Cancer
⚠️ Guideline GapMedian OS jumps from 14 months to 23.5 months; 5-year OS rises to 51.4% (vs 30.1%) for non-metastatic (Fang / Shchepotin).
NSCLC (Locally Advanced)
⚠️ Guideline Gap1-year local Progression-Free Survival (PFS) is effectively doubled (67.5% vs. 29.0%) (Mitsumori et al.).
Level 2/3 Evidence: Breaking the Survival Plateau
Where modern pharmacology struggles for marginal gains, thermal synergy delivers a paradigm shift.
Glioblastoma (GBM)
⚠️ Guideline Gap1-year survival rate nearly doubled, climbing from 37% (Stupp Protocol) to 73% (+36% absolute gain) via electro-hyperthermia (Fiorentini et al.).
Pancreatic Cancer
⚠️ Guideline GapA 2.2x survival multiplier, extending median OS to approximately 20 months compared to the historical 9-month baseline (Fiorentini et al.).
Malignant Melanoma
✅ ESMO & NCCN GuidelinesAchieving 40-50% Complete Response (CR) rates utilizing Hyperthermic Isolated Limb Perfusion (HILP) for in-transit disease (Vrouenraets et al.).
Metastatic Colorectal Cancer
✅ ESMO & NCCN GuidelinesMedian OS extended by an additional 12 to 24 months through HIPEC integration for peritoneal carcinomatosis (Chua et al.).
Hepatocellular Carcinoma (HCC)
⚠️ Guideline GapObjective Response Rates (ORR) increased to 40-60% when combined with transarterial chemoembolization (TACE) (Vogl et al.).
The Ultimate Paradox & The Universal Multiplier
Addressing the evidence-guideline inversion and quantifying the pan-tumor thermal synergy.
1. The Evidence-Guideline Inversion
It is a profound clinical paradox that Level 2/3 evidence (e.g., HIPEC for CRC, HILP for Melanoma) is formally integrated into ESMO/NCCN guidelines, while Level 1A and 1B evidence (e.g., LACC, Gastric, NSCLC) remains trapped in a regulatory void.
The Critical Question for the Assembly:
“Must ESHO proactively force a massive lobbying effort, or is it ESMO’s core institutional responsibility to autonomously align its guidelines with indisputable Level 1A survival data?”
2. The Consistent Trend of Thermal Synergy – “~2.1x” Multiplier
Aggregating the clinical data from the previous cohorts creates a definitive trend. Hyperthermia acts as a universal, tumor-agnostic amplifier, regardless of the Standard of Care.
- Calculated Average: Across the quantified indications (STS, LACC, GBM, NSCLC, etc.), HT delivers a mathematical average multiplier of ~2.1x for Overall Survival (OS) and Complete Response (CR).
- Peak Amplification: Extreme synergy is observed with a 2.5x OS multiplier in LACC, 2.48x in STS, and up to 3.5x DFS in NMIBC.
- Palliative Outlier: Bone metastases symptom control reaches up to a 9-fold improvement in complete pain elimination compared to baseline.
The Cost of Omission: A Clinical Reality Check
Reversing the statistical lens on Level 1A survival multipliers.
We have established that adding hyperthermia yields a ~2.1x multiplier in survival outcomes. However, to truly understand the weight of this Level 1A evidence, we must view the data from the perspective of the patient receiving only the Standard of Care.
With all due respect to standard medical efforts, the statistical reality sounds an impossible-to-ignore alarm:
WITHOUT the addition of hyperthermia, 2 to 3 times more patients die, or they survive only half as long.
This dramatic human cost is the exact reason our oncology societies were founded. Bridging the gap between evidence and patient access is no longer just an academic goal—it is a moral imperative.
The Implementation Chasm: The Core Problem
Why theoretical guidelines fail at the national level without a functional regulatory framework.
1. The Knowledge Gap
Simply transcribing ESMO guidelines into national protocols is clinically useless if the medical workforce cannot execute them.
Currently, the vast majority of clinical oncologists possess only a theoretical awareness of hyperthermia, completely lacking practical expertise, operational training, and access to state-hospital infrastructure.
2. The Legislative “Gray Zone”
Consequently, hyperthermia treatments are pushed almost entirely into the private sector.
They are frequently administered by well-intentioned non-oncologist physicians who lack formal, state-recognized certification in thermotherapy. This exposes both patients and practitioners to immense legislative and malpractice risks.
The Ultimate Question for National Healthcare Systems:
“Even if ESMO universally mandates Level 1A guidelines tomorrow…
Who is legally certified and protected to put them into practice in our countries?“
The Ethical & Economic Imperative
“Perfecting clinical trials and advanced dosimetry is the academic ideal. Surviving today with good QoL is the patient’s reality.”
The Ethical Mandate
It is fundamentally unethical to deprive a patient of a validated therapy that can greatly multiply their overall survival and improve QoL simply because administrative bureaucracy trails behind science.
We cannot wait for decades for “perfect” clinical trials and perfect dosimetry while patients suffer today.
Eradicating Financial Toxicity
The lack of DRG reimbursement codes and the imposition of a 21% VAT barrier on life-extending technology artificially restricts public access.
Access to OS improvements must be dictated strictly by clinical need, never by socio-economic status.
The SRHO Roadmap: Practical Solutions For Medical Professionals
Providing medical professionals with standard training, certification, and legislative protection.1. The Legislative Blueprint
- Implementation of a 140-hour CME Curriculum hosted within Medical Universities.
- Official accreditation: “Certificate of Complementary Studies” granted by the Ministry of Health.
2. The Hybrid Curriculum
- Hybrid Format: Online lectures from international authorities combined with physical clinical rotations.
- Specialized Teaching: Instructors focus exclusively on their niche (advanced thermometry, WBH, capacitive RF).
- Open Invitation: We actively welcome European colleagues to join our teaching faculty.
3. The Pragmatic Approach
We adopted this model following successful pathways of other medical societies (e.g., HBOT, Ozone Therapy). While this may not be absolute academic perfection, and we welcome further suggestions, it is a massive leap forward—infinitely better than nothing.
4. United Action & Synergy
“Divide et impera” is a flawed strategy. Remaining scattered weakens our collective impact.
By uniting our efforts (ESHO – !CENTRAL! with SRHO, SIIO, DGHT eV, SEOR,etc !local! ), we can effectively transform validated clinical evidence into national health policy across Europe.
The SRHO Roadmap: Practical solutions for clinics & hospitals
Quality Assurance: A Bridge, Not a Barrier
Aligning with ESHO/DGHT Guidelines through a pragmatic, tiered approach.
Tier 1: Standard Clinical Integration (Baseline)
Prioritizes immediate patient access utilizing native monitoring systems integrated directly within MDR-certified equipment. The absence of advanced 3D spatial thermometry must never serve as an administrative or clinical barrier to life-saving treatment (especially for MDR WBH/CCHT/mEHT equipments) (DGHT practical standards).
Tier 2: Centers of Excellence (The Precision Ideal)
Facilitates the progressive transition toward strict ESHO academic standards, utilizing non-invasive 3D modeling and advanced real-time metrics (e.g., CEM43°C T90) to drive ultimate precision oncology and reproducibility.
The Practical Implementation Mandate
Clinical centers must start immediately at Tier 1 so no patient is deprived of a proven survival multiplier today, while actively building toward Tier 2 as the ultimate institutional standard.
Institutional Adoption: Overcoming the Infrastructure Barrier
A certified doctor without infrastructure cannot treat. Moving HT into state hospital protocols.
1. The Equipment Bottleneck
Training is only step one. Hyperthermia requires significant capital expenditure (CAPEX).
It is unsustainable to rely solely on private clinics. State and public hospitals must provide this infrastructure to guarantee democratic access to life-saving technology, regardless of the patient’s financial status.
2. Physician-Driven Demand
Hospitals adopt what their top specialists demand. By educating and certifying a critical mass of oncologists, we generate powerful bottom-up pressure.
When certified doctors officially request HT facilities as a clinical necessity for their patients, hospital management is compelled to initiate procurement.
3. The Economic Catalyst for Management
To convince hospital managers and national insurance bodies, we frame HT not as an expense, but as an efficiency tool. Integrating HT ultimately reduces systemic costs by preventing mutilating surgeries, shortening hospitalizations, and mitigating costly complications from traditional therapies.
The Economic Viability: A Methodology Benchmark
Demonstrating cost-effectiveness through clinical integration (Benchmark Study: mEHT).
The Cost-Saving Pathway
Methodology: Cost-Effectiveness Analysis (CEA) over a 3-year horizon.
Initial investment is rapidly eclipsed by downstream savings. By doubling disease-free survival, HT reduces patients returning with recurrences who require expensive second-line treatments.
Affordability, non-invasiveness, and ease of integration mean it can be deployed without significant infrastructure or training in resource-constrained settings.
82.2% Probability
of realizing absolute cost savings over a 3-year horizon.
The Pharmacoeconomic Reality: Systemic Efficiency
Comparing the CAPEX of Hyperthermia infrastructure to the annual OPEX of modern Immunotherapy.
1. The Financial Toxicity of SOC
A standard one-year treatment of approved immunotherapies (e.g., Nivolumab or Ipilimumab) averages between €100,000 and €150,000. For combined therapies, the cost for a single patient can easily exceed €250,000 per year.
2. The Sustainability of HT Infrastructure
Equipping a department with an advanced Hyperthermia system requires a one-time capital expenditure (CAPEX) of €70,000 to €150,000. This amortizable infrastructure has a lifespan of nearly a decade, treating thousands of patients.
By acting as a powerful immunomodulator and chemosensitizer, HT maximizes the response rate of expensive systemic drugs.
It ensures that public funds (€150k+/patient) are not wasted on resistant or immunologically “cold” tumors.
The Mathematical Truth
1 HT System (treats thousands over 10 years)
EQUALS
1 Year of Immunotherapy (for ONE patient).
Patient Advocacy & Grassroots Demand
Empowering the patient voice to create political pressure from the bottom up.
Direct Education & Awareness
Launching a national program of free information sessions organized directly within patient support groups. Goal: Providing an objective, scientific, and accessible perspective on hyperthermia benefits.
Creating Critical Mass
Authorities respond to public pressure. By informing patients, we translate a clinical need into legitimate public demand, compelling decision-makers to analyze reimbursement to meet patient needs.
The SRHO Roadmap & Institutional Synergy
Overcoming the regulatory vacuum in Romania and other countries in EU (FRANCE, UK!) despite Level 1A evidence.
International Endorsement for SRHO WHITEPAPER
-
- Dr. Hüseyin Şahinbaş (President DGHT e.V.) – reviewed, confirmed & co-signed.
- Prof. Dr. Giammaria Fiorentini (President SIIO) – reviewed, co-authored, validated exceptional value.
- Prof. Dr. Jorge Contreras Martínez (President SEMHIO) – reviewed, pledged total support.
- Prof. Dr. Niloy Datta – scientific reviewer.
- Prof. Dr. Hans Crezee (President ESHO) – under review (ongoing).
- “We request the ESHO Board to form a joint SRHO-ESHO Task Force for the standardization of QA/QC protocols in South-Eastern Europe.”
Transforming Science into Standard of Care
Thank you to our European partners for your continuous support, validations, and the collaborative effort to build this educational roadmap.
Discussion / Q&A Prompt:
“With Level 1A evidence firmly established, how can we best leverage our united European institutional weight to convince national authorities to finally place hyperthermia on the oncologist’s practical workbench?”